Definition, origins and examples of peptide-related impurities in synthetic peptide drug substances and products.
Peptide-related impurities are peptide-like structures that retain elements of the active peptide sequence. They are distinct from small process impurities such as residual reagents, solvents or elemental impurities.
Synthetic origins
Deletion, insertion, truncation, stereochemical variation and incomplete or side reactions can create IRPs during synthesis.
Degradation origins
Oxidation, hydrolysis, isomerization, deamidation and other transformations can generate related peptide species during processing or storage.
Higher-order species
Dimers, oligomers and aggregates can require separate consideration depending on the product and mechanism.
Why classification matters
IRPs and ordinary small-molecule impurities do not necessarily follow the same analytical and toxicological qualification framework.
Frequently asked questions
Are residual solvents IRPs?
No.
Can degradation create IRPs?
Yes.
Are all IRPs immunogenic?
No, but immunogenicity can be a central safety concern.
Why distinguish IRPs from small impurities?
Because the relevant regulatory and safety paradigms differ.
